Ardelyx Stock Drops Significantly After Opting Out of CMS Payment Program for Xphozah

Tuesday, 2 July 2024, 15:06
Ardelyx (ARDX) saw a sharp decline of 20% in its stock value on Tuesday as the company announced its choice not to seek inclusion of Xphozah in the CMS's TDAPA payment program. This decision has prompted market concerns and raised questions about the future revenue impact on Ardelyx. Investors are closely monitoring the implications of this development on the company's financial performance.
Seeking Alpha
Ardelyx Stock Drops Significantly After Opting Out of CMS Payment Program for Xphozah

Ardelyx Stock Plummets 20%

Ardelyx (ARDX) stock tumbled 20% Tuesday after the company said it has decided not to apply to include its drug Xphozah in the CMS's TDAPA payment program.

Market Reaction and Concerns

  • Investors are closely monitoring the implications on Ardelyx.
  • Future Revenue Impact: Questions arise about the potential financial repercussions.

Read more here.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe